Suven Life Sciences, a Hyderabad-based pioneer in contract research and manufacturing services (CRAMS) will present pre-clinical data of its new chemical entities SUVN-502 and SUVN-507 at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience to be held on July 12-17, 2007at Melbourne, Australia.
The scientists from Suven Discovery Research will present new data for four promising areas of neuroscience namely Alzheimer's, Schizophrenia, Parkinson and obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient, the company said in a release.
The CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders. The company has several programmes in CNS disorder areas, focusing on novel approaches that may lead to the development of new therapies for patients, the release said.
The company is committed to neuroscience research and for development of new treatments for neurological disorders. The company's discovery research focus is on developing new chemical entities for central nervous system (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches, the release further said.
The company has informed that, with an intention to become collaborative research partner (CRP) for global life science companies it has embarked on new business model "Drug Discovery and Development Support Services" (DDDSS) post IP regime in 2005. Currently, it has R&D strength of more than 190 professionals with the state-of-the-art infrastructure for drug discovery and development activities with 30 clinical research professionals and the front-end project management services from New Jersey, USA.